Professional Media briefs: September 2013

Daniel Albert
Daniel Albert

Daniel Albert, editor of JAMA Ophthalmology for the past two decades, is now Distinguished Senior Editor at Ophthalmology: Journal of the American Academy of Ophthalmology. Albert continues as F.A. Davis Professor in the University of Wisconsin Medical School's Department of Ophthalmology and Visual Sciences.

The New England Journal of Medicine has refreshed Journal Watch, giving the resource a new name—NEJM Journal Watch—a new logo, and an enhanced website that includes enriched graphics. The mobile-optimized site will be gateless through August 30.

Elsevier's latest version of Molecular Biology is now an enhanced ePub3 book, which includes animations, interactive learning widgets, and Cell Press journal articles.

Oxford University Press will be publishing Bio­Science as of January 2014. The journal of the American Institute of Biological Sciences tells MM&M that its contract with the University of California Press was ending, and OUP won out in the bidding process. “We are very pleased at the opportunities for increased international exposure,” the institute's executive director Richard O'Grady said in a statement.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.